A Study of PF-08046052/SGN-EGFRd2 in Advanced Solid Tumors

Study Summary

This study will test the safety of a drug called PF-08046052/SGN-EGFRd2 in participants with advanced solid tumors. It will also study the side effects of this drug. A side effect is anything a drug does to the body besides treating the disease. Participants will have cancer that cannot be removed (unresectable) or has spread through the body (metastatic). This study will have three parts. Parts A and B of the study will find out how much PF-08046052/SGN-EGFRd2 should be given to participants. Part C will use the dose found in parts A and B to find out how safe PF-08046052/SGN-EGFRd2 is and if it works to treat solid tumor cancers.

Conditions

Colorectal Neoplasms Carcinoma, Non-Small-Cell Lung Squamous Cell Carcinoma of the Head and Neck Pancreatic Ductal Adenocarcinoma

Interventions / Drugs

PF-08046052

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment68 participants

Primary Completion—

Lead SponsorSeagen, a wholly owned subsidiary of Pfizer

Data Retrieved2026-04-11 02:55:53.189827+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.